MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.44
+1.18
+4.67%
After Hours: 26.44 0 0.00% 16:00 08/06 EDT
OPEN
25.83
PREV CLOSE
25.26
HIGH
27.24
LOW
25.77
VOLUME
489.27K
TURNOVER
--
52 WEEK HIGH
27.59
52 WEEK LOW
9.01
MARKET CAP
1.46B
P/E (TTM)
-16.5353
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RCKT stock price target is 36.22 with a high estimate of 46.00 and a low estimate of 31.00.

EPS

RCKT News

More
Rocket Pharmaceuticals EPS beats by $0.06
Rocket Pharmaceuticals (NASDAQ:RCKT): Q2 GAAP EPS of -$0.45 beats by $0.06. Cash, equivalents and investments of $249.8M. Press Release
seekingalpha · 1d ago
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter that ended June 30, 2020, along
Business Wire · 1d ago
Rocket Pharma initiates RP-L301 study for red blood cell disorder
Rocket Pharmaceuticals (NASDAQ:RCKT) announces that the first patient has received investigational therapy in the Phase 1 clinical trial of RP-L301, the le
seekingalpha · 07/13 16:51
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
Benzinga · 07/13 11:10
J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels
TipRanks · 07/08 17:53
Rocket Pharmaceuticals initiated at overweight with $38 price target at JPMorgan
marketwatch.com · 07/02 10:29
JP Morgan Initiates Coverage On Rocket Pharmaceuticals with Overweight Rating, Announces Price Target of $38
JP Morgan initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight rating and announces Price Target of $38.
Benzinga · 07/02 09:29
FDA signs off on Rocket Pharma's gene therapy for infantile malignant osteopetrosis
Seeking Alpha - Article · 06/29 12:26

Industry

Biotechnology & Medical Research
-0.96%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.
More

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.